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 Tapmeier  et al. 10 also used anti-CD4 
antibody treatment in wild-type UUO 
mice, which caused at least a 50 % reduc-
tion in collagen deposition, providing a 
 prima facie case for CD4   +   T cells pro-
moting interstitial fi brosis in this model. 
The CD4 antibody treatment did not 
alter tubular damage or the number of 
F4 / 80   +   macrophages, consistent with the 
 RAG   −  /  −   studies. Intriguingly, the CD4 
antibody treatment resulted in a twofold 
increase in the interstitial   -SMA   +  
myofibroblast population, while sup-
pressing renal fi brosis. 10 Th us, removal 
of all lymphocytes in  RAG   −  /  −   mice sup-
pressed interstitial fibrosis in the 
obstructed kidney together with a reduc-
tion in   -SMA   +   myofi broblasts, whereas 
depletion of CD4   +   T cells using antibody 
treatment also reduced fi brosis but with 
an increase in   -SMA   +   myofi broblasts. 
Th ese apparently contradictory results 
are diffi  cult to reconcile, and a further 
complicating factor is the short duration 
of CD4 antibody treatment such that 
CD4 T cells reappeared in the obstructed 
kidney later in the disease course. 
 In summary, two recent studies pro-
vide evidence, particularly by the use of 
depleting CD4 antibody treatment, that 
CD4   +   T cells promote renal fi brosis in 
the obstructed kidney. 7,8 Many questions 
remain regarding the potential mecha-
nisms involved in this process. As illus-
trated in  Figure 1 , there are at least three 
potential mechanisms by which CD4   +   T 
cells may promote renal fibrosis. It is 
hoped that these intriguing studies will 
stimulate further research into the direct 
actions in T cells in renal fi brosis — a path-
ologic process that is in desperate need of 
innovative therapies. 
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 In this issue of  Kidney International , 
Lertdumrongluk  et al. 1 examine the rela-
tionship between the pharmacokinetics 
of mycophenolic acid (MPA) and the 
response to treatment in patients with 
class III and IV lupus nephritis (Interna-
tional Society of Nephrology / Renal 
Pathology Society category). Th e topic 
of therapeutic drug monitoring (TDM) 
of MPA and the effi  ciency of the therapy 
in lupus nephritis treatment with the use 
of mycophenolate mofetil (MMF) and 
enteric-coated mycophenolate sodium 
(EC-MPS) warrants further attention. 
 Lupus nephritis is a kidney disorder 
affecting approximately three of every 
10,000 people. Th e medical therapy for 
lupus nephritis depends on the severity of 
the disease. In general, corticosteroids are 
prescribed for mild disease, whereas more 
severe disease requires treatment with 
immunosuppressive drugs. Th e two most 
commonly used agents are MMF and 
intravenous cyclophosphamide. In a 
recent study, patients with class III and IV 
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 Mycophenolate mofetil, an immunosuppressant approved for the 
prevention of transplant rejection, has been used in patients with lupus 
nephritis. Lertdumrongluk  et al. 1 suggest that mycophenolic acid 
exposure may predict therapeutic responses in severe lupus nephritis, 
and their initial results confirm that hypothesis. However, it seems that 
enteric-coated mycophenolate sodium should not be administered to 
patients provided with therapeutic drug monitoring. 
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disease were more likely to benefi t from 
MMF than from cyclophosphamide. 2 As 
a result, MMF is now considered to be an 
alternative therapy for this disease. 
 Lertdumrongluk  et al. 1 present, for the 
fi rst time, the relationship between MPA 
exposure and the response to treatment 
in patients with class III and IV lupus 
nephritis. Th is study shows a pivotal role 
of TDM of MPA in the treatment of 
lupus nephritis, similar to minimizing 
the risk of acute rejection in transplanta-
tion ( Figure 1 ). Without doubt, MPA 
TDM is useful in clinical practice in 
solid-organ transplantation, in which the 
recommended MPA target exposure 










 Figure 1  |  The elements are joined just like a puzzle: the administered MMF, therapeutic 
monitoring of its concentration in blood, determined MPA exposure, and clinical 
outcome of lupus nephritis treatment. AUC, area under the concentration – time curve; MMF, 
mycophenolate mofetil; MPA, mycophenolic acid. 
(AUC) of 30 – 60  mg  × h / l) is directly cor-
related with minimization of renal allo-
graft rejection. 3,4 In contrast to MMF, 
there is a clear limitation to using TDM for 
MPA in patients treated with EC-MPS. 
With EC-MPS, delayed absorption results 
in delayed enterohepatic recirculation and 
subsequently in higher and more variable 
trough levels. Therefore, MPA trough 
monitoring will be more problematic for 
EC-MPS ( r 2 for correlation between 
trough level  and dose  –  inter val 
AUC  =  0.02). 5 Even more important is the 
higher pharmacokinetic variability of EC-
MPS compared with MMF, which is 
refl ected in a much more unpredictable and 
irregular concentration – time profi le and a 
higher variability in the main pharmacoki-
netic parameters, despite similar mean 
value. 6 Th erefore, in future investigations 
relating to TDM, patients should be treated 
only with MMF, as TDM of EC-MPS is 
problematic for the reasons stated above. 
 Further studies are needed to confi rm 
whether TDM of MPA is benefi cial for lupus 
nephritis treatment and to confi rm whether 
an AUC cutoff  of 45  mg  × h / l in severe lupus 
nephritis is indeed the correct value. 
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